{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=39",
    "query": {
      "condition": "Recurrent Gliomas",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 1033,
    "total_pages": 104,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Gliomas&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-22T20:16:34.508Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00445588",
      "title": "Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 56,
      "start_date": "2007-01",
      "completion_date": "2009-08",
      "has_results": true,
      "last_update_posted_date": "2016-04-27",
      "last_synced_at": "2026-10-22T20:16:34.508Z",
      "location_count": 9,
      "location_summary": "Birmingham, Alabama • Tampa, Florida • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00445588"
    },
    {
      "nct_id": "NCT01682746",
      "title": "Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain Tumor, Recurrent"
      ],
      "interventions": [
        {
          "name": "Photofrin (porfimer sodium) & photodynamic therapy.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Harry T Whelan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 5,
      "start_date": "2013-03",
      "completion_date": "2018-06-29",
      "has_results": false,
      "last_update_posted_date": "2019-02-25",
      "last_synced_at": "2026-10-22T20:16:34.508Z",
      "location_count": 1,
      "location_summary": "Wauwatosa, Wisconsin",
      "locations": [
        {
          "city": "Wauwatosa",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01682746"
    },
    {
      "nct_id": "NCT06072586",
      "title": "A Phase 0/1 Study of BDTX-1535 in Recurrent High-Grade Glioma (rHGG) and Newly Diagnosed Glioblastoma (nGBM) Participants With EGFR Alterations or Fusions",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "High Grade Glioma",
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "BDTX-1535",
          "type": "DRUG"
        },
        {
          "name": "BDTX-1535 combined with radiation therapy",
          "type": "DRUG"
        },
        {
          "name": "BDTX-1535 combined with temozolomide and radiation therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "St. Joseph's Hospital and Medical Center, Phoenix",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 82,
      "start_date": "2023-10-18",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-10-16",
      "last_synced_at": "2026-10-22T20:16:34.508Z",
      "location_count": 2,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06072586"
    },
    {
      "nct_id": "NCT00290771",
      "title": "Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Glioblastoma Multiforme (GBM)"
      ],
      "interventions": [
        {
          "name": "Imatinib tablets",
          "type": "DRUG"
        },
        {
          "name": "Hydroxyurea capsules",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 231,
      "start_date": "2006-02",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2011-05-16",
      "last_synced_at": "2026-10-22T20:16:34.508Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00290771"
    },
    {
      "nct_id": "NCT04225039",
      "title": "Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma"
      ],
      "interventions": [
        {
          "name": "INCMGA00012",
          "type": "DRUG"
        },
        {
          "name": "INCAGN01876",
          "type": "DRUG"
        },
        {
          "name": "SRS",
          "type": "DRUG"
        },
        {
          "name": "Brain surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2020-06-23",
      "completion_date": "2029-04-30",
      "has_results": true,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-10-22T20:16:34.508Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04225039"
    },
    {
      "nct_id": "NCT00335764",
      "title": "Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Adult Giant Cell Glioblastoma",
        "Adult Glioblastoma",
        "Adult Gliosarcoma",
        "Recurrent Adult Brain Tumor"
      ],
      "interventions": [
        {
          "name": "sorafenib tosylate",
          "type": "DRUG"
        },
        {
          "name": "erlotinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "tipifarnib",
          "type": "DRUG"
        },
        {
          "name": "temsirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 92,
      "start_date": "2006-04",
      "completion_date": "2012-09",
      "has_results": true,
      "last_update_posted_date": "2018-07-02",
      "last_synced_at": "2026-10-22T20:16:34.508Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • San Francisco, California • Boston, Massachusetts + 4 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00335764"
    },
    {
      "nct_id": "NCT03295396",
      "title": "ONC201 in Adults With Recurrent H3 K27M-mutant Glioma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioma"
      ],
      "interventions": [
        {
          "name": "Dordaviprone (ONC201)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 73,
      "start_date": "2017-10-30",
      "completion_date": "2023-07-19",
      "has_results": true,
      "last_update_posted_date": "2025-07-28",
      "last_synced_at": "2026-10-22T20:16:34.508Z",
      "location_count": 9,
      "location_summary": "San Francisco, California • Stanford, California • Ann Arbor, Michigan + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03295396"
    },
    {
      "nct_id": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Lymphoma",
        "Advanced Malignant Solid Neoplasm",
        "Bladder Carcinoma",
        "Breast Carcinoma",
        "Cervical Carcinoma",
        "Colon Carcinoma",
        "Colorectal Carcinoma",
        "Endometrial Carcinoma",
        "Esophageal Carcinoma",
        "Exocrine Pancreas Carcinoma",
        "Gastric Carcinoma",
        "Glioma",
        "Head and Neck Carcinoma",
        "Hematopoietic and Lymphoid Cell Neoplasm",
        "Kidney Carcinoma",
        "Liver Carcinoma",
        "Lung Carcinoma",
        "Lymphoma",
        "Malignant Uterine Corpus Neoplasm",
        "Malignant Uterine Neoplasm",
        "Melanoma",
        "Multiple Myeloma",
        "Ovarian Carcinoma",
        "Prostate Carcinoma",
        "Rectal Carcinoma",
        "Recurrent Bladder Carcinoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Cervical Carcinoma",
        "Recurrent Colon Carcinoma",
        "Recurrent Colorectal Carcinoma",
        "Recurrent Esophageal Carcinoma",
        "Recurrent Gastric Carcinoma",
        "Recurrent Glioma",
        "Recurrent Head and Neck Carcinoma",
        "Recurrent Liver Carcinoma",
        "Recurrent Lung Carcinoma",
        "Recurrent Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Malignant Uterine Corpus Neoplasm",
        "Recurrent Melanoma",
        "Recurrent Multiple Myeloma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Pancreatic Carcinoma",
        "Recurrent Prostate Carcinoma",
        "Recurrent Rectal Carcinoma",
        "Recurrent Skin Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Multiple Myeloma",
        "Skin Carcinoma",
        "Thyroid Gland Carcinoma"
      ],
      "interventions": [
        {
          "name": "Adavosertib",
          "type": "DRUG"
        },
        {
          "name": "Afatinib",
          "type": "DRUG"
        },
        {
          "name": "Afatinib Dimaleate",
          "type": "DRUG"
        },
        {
          "name": "Binimetinib",
          "type": "DRUG"
        },
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Capivasertib",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Copanlisib",
          "type": "DRUG"
        },
        {
          "name": "Copanlisib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Crizotinib",
          "type": "DRUG"
        },
        {
          "name": "Cytology Specimen Collection Procedure",
          "type": "OTHER"
        },
        {
          "name": "Dabrafenib",
          "type": "DRUG"
        },
        {
          "name": "Dabrafenib Mesylate",
          "type": "DRUG"
        },
        {
          "name": "Dasatinib",
          "type": "DRUG"
        },
        {
          "name": "Defactinib",
          "type": "DRUG"
        },
        {
          "name": "Defactinib Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Echocardiography Test",
          "type": "PROCEDURE"
        },
        {
          "name": "Erdafitinib",
          "type": "DRUG"
        },
        {
          "name": "Fexagratinib",
          "type": "DRUG"
        },
        {
          "name": "Ipatasertib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Larotrectinib",
          "type": "DRUG"
        },
        {
          "name": "Larotrectinib Sulfate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Multigated Acquisition Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Osimertinib",
          "type": "DRUG"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Pertuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "PI3K-beta Inhibitor GSK2636771",
          "type": "DRUG"
        },
        {
          "name": "Radiologic Examination",
          "type": "PROCEDURE"
        },
        {
          "name": "Radionuclide Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Relatlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sapanisertib",
          "type": "DRUG"
        },
        {
          "name": "Sunitinib Malate",
          "type": "DRUG"
        },
        {
          "name": "Taselisib",
          "type": "DRUG"
        },
        {
          "name": "Trametinib",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Trastuzumab Emtansine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ulixertinib",
          "type": "DRUG"
        },
        {
          "name": "Vismodegib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6452,
      "start_date": "2015-08-17",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-22T20:16:34.508Z",
      "location_count": 1405,
      "location_summary": "Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 847 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02465060"
    },
    {
      "nct_id": "NCT00503724",
      "title": "Enzastaurin in Treating Young Patients With Refractory Primary CNS Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "enzastaurin hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pediatric Brain Tumor Consortium",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 32,
      "start_date": "2007-06",
      "completion_date": "2010-05",
      "has_results": false,
      "last_update_posted_date": "2012-03-06",
      "last_synced_at": "2026-10-22T20:16:34.508Z",
      "location_count": 8,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Chicago, Illinois + 5 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00503724"
    },
    {
      "nct_id": "NCT02644291",
      "title": "Phase I Study of Mebendazole Therapy for Recurrent/Progressive Pediatric Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Medulloblastoma",
        "Astrocytoma, Grade III",
        "Glioblastoma",
        "Anaplastic Astrocytoma",
        "Brain Stem Neoplasms, Malignant",
        "Oligodendroblastoma",
        "Anaplastic Oligodendroglioma",
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "Mebendazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 16,
      "start_date": "2016-05",
      "completion_date": "2022-06-09",
      "has_results": false,
      "last_update_posted_date": "2022-06-23",
      "last_synced_at": "2026-10-22T20:16:34.508Z",
      "location_count": 2,
      "location_summary": "St. Petersburg, Florida • Baltimore, Maryland",
      "locations": [
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02644291"
    }
  ]
}